Lesional dosimetry in 131I refractory metastatic differentiated thyroid cancer with BRAFp.V600E or RAS mutation treated with trametinib +/- dabrafenib followed by radioactive iodine.

doi:10.1016/j.ejmp.2026.105769

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Lesional dosimetry in 131I refractory metastatic differentiated thyroid cancer with BRAFp.V600E or RAS mutation treated with trametinib +/- dabrafenib followed by radioactive iodine.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) - 1 May 2026

Anizan Nadège, Pignard Alexandre, Borget Isabelle, Lamartina Livia, Schlumberger Martin, Broggio David, Leboulleux Sophie, Lamart Stéphanie

Abstract excerpt

PURPOSE: In the MERAIODE phase II prospective trial (NCT03244956), patients with radioactive iodine refractory metastatic differentiated thyroid cancer (DTC) were treated with trametinib +/- dabrafenib before the administration of 5.5 GBq of 131I. A post-therapeutic lesional dosimetry study was conducted to assess the correlation between lesion absorbed doses and tumour response. METHODS: Absorbed doses (AD) were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Iodine Radioisotopes

Share to Neoplasm Metastasis

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Share to ras Proteins

Share to Thyroid Neoplasms

Source

Open in PubMed

Identifiers

PMID: 41861727
DOI: 10.1016/j.ejmp.2026.105769

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lesional dosimetry in 131I refractory metastatic differentiated thyroid cancer with BRAFp.V600E or RAS mutation treated with trametinib +/- dabrafenib followed by radioactive iodine.PMID 41861727Read ↗

A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer.Semantic proximity Read ↗

Toward precision biomarker RAI therapy of well-differentiated thyroid cancer: linking administered radioactivity (MBq) to a prescribed lesion radiation-absorbed dose (cGy)Semantic proximity Read ↗

Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.Semantic proximity Read ↗

Restoring Radioiodine Avidity in Radioiodine-refractory Differentiated Thyroid Cancer With Genotype-guided MAPK Inhibition and Dosimetry-guided Radioiodine.Semantic proximity Read ↗

Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology.Semantic proximity Read ↗

Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.Semantic proximity Read ↗

Clinico-pathological factors and 18 F-FDG PET/CT metabolic parameters for prediction of progression-free survival in Radioiodine Refractory Differentiated Thyroid CarcinomaSemantic proximity Read ↗

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.Semantic proximity Read ↗

Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases.Semantic proximity Read ↗

Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial.Semantic proximity Read ↗

Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.Semantic proximity Read ↗

Short-Term BRAF Inhibition with Dabrafenib induced redifferentiation in a subset of patients with BRAF V600E-Mutant papillary thyroid carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.